pegzilarginase-nbln 2 MG per 0.4 ML Injection

RxCUI: 2738664
RxNorm name: pegzilarginase-nbln 2 MG per 0.4 ML Injection
Display name: pegzilarginase-nbln 2 MG per 0.4 ML Injection
Full name: pegzilarginase-nbln 2 MG per 0.4 ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:22

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761211	Loargys	pegzilarginase-nbln	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Loargys	PEGZILARGINASE-NBLN	Immedica Pharma US Inc.	d5ceabf2-43a0-4746-9371-d98a39cf6cfc	2026-02-23	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2738664

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
d5ceabf2-43a0-4746-9371-d98a39cf6cfc	pegzilarginase-nbln 2 MG in 0.4 ML Injection [PSN] · 0.4 ML pegzilarginase-nbln 5 MG/ML Injection [SCD] · pegzilarginase-nbln 2 MG per 0.4 ML Injection [SY] · pegzilarginase-nbln 5 MG/ML per 0.4 ML Injection [SY]	4	1	These highlights do not include all the information needed to use LOARGYS safely and effectively. See full prescribing information for LOARGYS . LOARGYS (pegzilarginase-nbln) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2026	20260223